MYRIAD PHARMA (NASDAQ:MYRX)

View All ReportsStreetInsider.com Reports on MYRX

Nov 19, 2009 07:13 AM Piper Jaffray Upgrades Myriad Pharmaceuticals (MYRX) to Neutral

Nov 18, 2009 10:16 AM Morning Movers 11/18: ABK, CHS, LDK, RDN Higher; ONCY, NANO, EXEL, ADSK, CNQR Lower

Nov 18, 2009 08:46 AM Myriad Pharma (MYRX) Presents Initial Phase 2a Data for Azixa

Nov 12, 2009 05:24 PM Myriad Pharma (MYRX) Posts Q1 Loss of $0.44, Better Y/Y; Revs Down

Oct 13, 2009 05:38 PM After-Hours Movers 10/13: CNO, MYRX, VOXX, INTC, GPI, CSX Higher; BMTI, PURE Lower

View All Press ReleasesCompany Press Releases on MYRX

Nov 23, 2009 09:51PM Myriad Pharmaceuticals Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference

Nov 18, 2009 08:00AM Initial Phase 2 Results for Myriad Pharmaceuticals' Azixa(TM) (MPC-6827) in Metastatic Melanoma

Nov 16, 2009 08:00AM Myriad Pharmaceuticals Confirms That MPC-3100, a Fully-Synthetic Hsp90 Inhibitor, is Orally-Bioavailable in Patients in Phase 1 Studies

Nov 12, 2009 05:21PM Myriad Pharmaceuticals Reports First Quarter FY' 2010 Financial Results

Oct 23, 2009 02:30PM Myriad Pharmaceuticals' Azixa(TM) is Efficacious in a Model of Human Brain Cancer and Its Activity is Additive With Avastin(R)

StreetInsider Reports on MYRX by Category

• Analyst Ratings
• Mergers and Acquisitions
• Earnings
• Guidance
• Stock Buybacks
• Dividends
• Retail Sales
• Management Changes
• Insider Trades
• View More Categories

View All BlogsBlogs on MYRX

Nov 19, 2009 11:35 AM Analyst upgrades, downgrades and initiations: CVS, FICO, HOTT, INTC, MNTA, TXN ...

Oct 5, 2009 04:48 AM Nine Companies Added to Potential Activist Targets

Sep 6, 2009 04:37 AM Three Stocks for Any Portfolio

View All FilingsSEC Filings on MYRX

Sep 28, 2009 05:11PM Form 10-K Myriad Pharmaceuticals, For: Jun 30

View All Comments Comments on recent MYRX articles

Edwin L
on Nov 20, 2009
at 11:43 AM Are you surprised? An independent regulatory authority has barred a former Piper Jaffray Cos. broker from working in the securities industry after finding that he engaged in insider trading earlier this year. Abhishek Uppal, of San Francisco, worked in Minneapolis-based Piper Jaffray’s investment banking department from 2007 to July 2009. Piper Jaffray (NYSE: PJC) was acting as a confidential advisor to SoftBrands Inc., of Minneapolis, in its dealings with possible buyers. Uppal knew about a pending acquisition of SoftBrands Inc. when he spent about $12,000 in June to buy 27,161 shares of the company, at 42 to 45 cents per share, according to the Washington, D.C.-based Financial Industry Regulatory Authority, or FINRA. SoftBrands’ stock nearly doubled days later, on June 12, when SoftBrands announced it was being acquired by San Francisco-based private-equity firm Golden Gate Capital and its Alpharetta, Ga.-based portfolio company Infor for 92 cents per share, at a total transaction value of about $80 million. The next business day, June 15, Uppal sold all his SoftBrands stock at 89 cents per share, and made a nearly $12,000 profit. In settling the matter, Uppal neither admitted nor denied the charges, according to FINRA.
Article: Piper Jaffray Upgrades Myriad Pharmaceuticals (MYRX) to Neutral

Tim Reitner
on Nov 19, 2009
at 04:17 PM 170 Musd is worth less than 100 Musd As a teacher it's very hard for me to explain that for my pupil. They are not that stupid. Wake me up please, this must be a bad joke! I thought stupidity was an obstacle for a career, but lately it seems like an opportunity.
Article: Piper Jaffray Upgrades Myriad Pharmaceuticals (MYRX) to Neutral

the bult
on Nov 19, 2009
at 11:41 AM illegal a few weeks after Piper Jaffrays initial coverage (giving a target price of $3,5) they announced owning 13% of the shares. During the weeks used for accumulating these shares the share price was well above their target price $3,5... what Piper Jeffray are doing should lead to legal action. i believe it sound to question an analyst who fails to mention the facts pointed out by the writers before me /concerned shareholder
Article: Piper Jaffray Upgrades Myriad Pharmaceuticals (MYRX) to Neutral

regas
on Nov 19, 2009
at 10:03 AM Bring in additional capital??? They are loaded with money!! Myriad Pharma have speaken to deaf ears. In the presentation in July where the so called analyst from PiperJaffray should have stayed awake and listened. They've been told that Myriad have sufficiient money to bring Azixa to market all by themselves. They don't need any partnership for that! Why share future revenue if they don't have to. But with Bevirimat, wich in comparison needs a very large study , they might need partnership. Listen learn and do right nex time!
Article: Piper Jaffray Upgrades Myriad Pharmaceuticals (MYRX) to Neutral

BaronTrenck2
on Nov 19, 2009
at 09:38 AM Price target It would be very interesting to have a look on how the target price $5 is calculated. I cannot see this "analysis" serious until I see some facts behind the price target.
Article: Piper Jaffray Upgrades Myriad Pharmaceuticals (MYRX) to Neutral

Comments on MYRX

No comments are currently available.

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?